Jaymie Sawyer
Member Board of Directors @Scarab Genomics
Signup · Get unlimited contacts
WORK HISTORY
Member Board of Directors @Scarab Genomics
Madison, WI, US
Scarab Genomics has created Clean Genome® E. coli, a unique, patented set of bacterial hosts for reliable, high efficiency production of protein and nucleic acid biopharmaceuticals. Troublesome genetic elements, including IS elements and cryptic phages, and many nonessential genes, have been removed from the genome, resulting in more efficient and more reliable production. Clean Genome® E. coli is, unlike other hosts, capable of continuous production, which has been implemented as C-Flow™. A typical 30-day C-Flow™ process yields 4.5 kg protein per month before purification at a mere 10-liter scale, dramatically reducing infrastructure requirements for substantial production volumes. Because production is continuous, conditions can be optimized on the fly, and because volumes are small, scale-up is rapid. Enabled by reduced genome strains, we sell research grade vaccine carrier proteins CRM197 and Protein D, and are developing continuous cGMP manufacturing of CRM197 for clinical needs. Scarab offers licensing options for research and for commercial production.
EDUCATION
University of Wisconsin-Madison
PhD, Genetics
University of Massachusetts Amherst
B.S., Zoology
SKILLS
ABOUT JAYMIE SAWYER
Well practiced in hybridoma screening, antibody engineering and phage display including automated high throughput discovery• Responsible for development of planar and bead based multiplexed immunoassays for RUO, IVD and clinical markets • Strong track record in assessing and implementing advanced technologies; including design of feasibility studies and application development for microfluidic systems and novel detection technologies • Highly effective at managing collaborations for both Fortune 500 “customers” and Biotech technology providers • Career progression of roles with increasing responsibilities in biotech including diagnostics, therapeutics and research reagents and in companies ranging from start ups to multinationals.Specialties: R&D leadership, multiplexed immunoassay development for RUO, IVD and Bioanalytics Antibody engineering, phage display, hybridoma screening, assessing and implementing advanced technologies, hiring and mentoring scientists
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.